TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18030112

Group type: EXPERIMENTAL
Intervention: Fresh botulinum toxin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Refrigerated botulinum toxin
Number of subjects: 45
Study: 16051709

Group type: EXPERIMENTAL
Intervention: Geometric mean of systolic and diastolic aortic pressures
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Empirical formulas for MAP estimation
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (n = 31)
Number of subjects: 139
Study: 11973410

Group type: EXPERIMENTAL
Intervention: Imidapril
Number of subjects: 69

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Nitroglycerin (sublingual administration)
Number of subjects: 69

Group type: COMPARATOR
Intervention: NG‐monomethyl‐l‐arginine (infusion)
Number of subjects: 69
Study: 10962387

Group type: EXPERIMENTAL
Intervention: triple therapy + ranitidine (n = 180)
Number of subjects: 343

Group type: COMPARATOR
Intervention: triple therapy alone (n = 163)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: triple therapy + ranitidine
Number of subjects: 343

Group type: COMPARATOR
Intervention: triple therapy alone
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: H. pylori eradication achieved
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: H. pylori eradication failed
Number of subjects: 343
Study: 8987446

Group type: EXPERIMENTAL
Intervention: 2% erythromycin gel
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 2
Study: 1600584

Group type: EXPERIMENTAL
Intervention: 0.6 micrograms yeast-derived hepatitis B vaccine
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 1.25 micrograms yeast-derived hepatitis B vaccine
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 2.5 micrograms yeast-derived hepatitis B vaccine
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 5.0 micrograms yeast-derived hepatitis B vaccine
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: All dosages of yeast-derived hepatitis B vaccine
Number of subjects: 122
Study: 6230611

Group type: EXPERIMENTAL
Intervention: Electronic infusion controller (IVAC 230)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard infusion method (control group)
Number of subjects: 0
Study: 29236550

Group type: EXPERIMENTAL
Intervention: E-cigarette advertisements (n=352)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Control advertisements (n=320)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: E-cigarette advertisements (current smokers, n=31)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Control advertisements (current smokers, n=31)
Number of subjects: 802
Study: 29526749

Group type: EXPERIMENTAL
Intervention: Intranasal administration of Oxytocin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27356705

Group type: EXPERIMENTAL
Intervention: Group training based on the Health Belief Model (HBM)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 330
Study: 25445613

Group type: EXPERIMENTAL
Intervention: Lantigen B (TG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (PG)
Number of subjects: 120
Study: 23070669

Group type: EXPERIMENTAL
Intervention: Initial Yoga (IY) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced wait-list control (WLC) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-minute walk distance (6MW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distress related to dyspnea (DD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional performance (FPI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological well-being (anxiety and depression)
Number of subjects: 0
Study: 20926021

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Rabeprazole 10 mg/day
Number of subjects: 23
Study: 17768624

Group type: EXPERIMENTAL
Intervention: Unilateral approach
Number of subjects: 52

Group type: COMPARATOR
Intervention: Bilateral approach
Number of subjects: 52
Study: 15701497

Group type: EXPERIMENTAL
Intervention: Video-imaging (VI)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Binocular direct-vision (BDV)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Monocular direct-vision (MDV)
Number of subjects: 24
Study: 12768912

Group type: EXPERIMENTAL
Intervention: High dose of eptifibatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10597554

Group type: EXPERIMENTAL
Intervention: Dopamine infusion (3 micrograms.kg‐1.min‐1) (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dextrose infusion (control) (Group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 8605791

Group type: EXPERIMENTAL
Intervention: 11 ppm inhaled nitric oxide
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 60 ppm inhaled nitric oxide
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 40 ppm inhaled nitric oxide
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 10 ppm inhaled nitric oxide
Number of subjects: 19
Study: 29766634

Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparators (placebo, sitagliptin, exenatide extended release, insulin glargine)
Number of subjects: 0
Study: 26251112

Group type: EXPERIMENTAL
Intervention: Reminiscence therapy (30-35 minutes, once a week for 12 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no reminiscence therapy)
Number of subjects: 62
Study: 24025983

Group type: EXPERIMENTAL
Intervention: Mericitabine 500 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Mericitabine 1000 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Mericitabine 2000 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Mericitabine (all doses)
Number of subjects: 64
Study: 23134382

Group type: EXPERIMENTAL
Intervention: Pay-for-performance program (Advancing Quality)
Number of subjects: 134435

Group type: COMPARATOR
Intervention: Control group (other hospitals in England)
Number of subjects: 134435
Study: 20216021

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance for femoral nerve blocks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance for sciatic nerve blocks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance
Number of subjects: 11

Group type: COMPARATOR
Intervention: Alternative techniques (control)
Number of subjects: 11
Study: 17935461

Group type: EXPERIMENTAL
Intervention: Domestic violence workshop
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control workshop
Number of subjects: 27
Study: 15679515

Group type: EXPERIMENTAL
Intervention: LEV 1,000 mg
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: LEV 333 mg
Number of subjects: 883

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 883
Study: 12215329

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound-guided embryo transfer
Number of subjects: 374

Group type: COMPARATOR
Intervention: Control group (no ultrasound guidance)
Number of subjects: 374
Study: 9931651

Group type: EXPERIMENTAL
Intervention: Standard pancreatectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: R0 resections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant radiochemotherapy
Number of subjects: 0
Study: 7649596

Group type: EXPERIMENTAL
Intervention: Sahaja yoga meditation for 6 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Postural exercises mimicking Sahaja yoga for 6 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (epileptic control)
Number of subjects: 32
Study: 2669119

Group type: EXPERIMENTAL
Intervention: Omeprazole (30 mg)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Cimetidine (1 g)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Non-smokers
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Healed prepyloric ulcer
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Healed corpus ulcer
Number of subjects: 217
Study: 353659

Group type: EXPERIMENTAL
Intervention: Low dose heparin (t.i.d.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low dose heparin (t.i.d.) combined with aspirin
Number of subjects: 40
Study: 31402492

Group type: EXPERIMENTAL
Intervention: QTcA (patient-specific QT correcting algorithm)
Number of subjects: 1930

Group type: EXPERIMENTAL
Intervention: QTcA (severely prolonged)
Number of subjects: 1930

Group type: EXPERIMENTAL
Intervention: QTcA (prolonged)
Number of subjects: 1930

Group type: EXPERIMENTAL
Intervention: QTcB (prolonged)
Number of subjects: 1930

Group type: EXPERIMENTAL
Intervention: QTcB
Number of subjects: 1930

Group type: EXPERIMENTAL
Intervention: QTcA
Number of subjects: 1930
Study: 26769823

Group type: EXPERIMENTAL
Intervention: Time and Place Management (TPM) intervention
Number of subjects: 437
Study: 26058489

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham PEMFs
Number of subjects: 50
Study: 23834132

Group type: EXPERIMENTAL
Intervention: Intranasal azelastine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isotonic sea water nasal spray
Number of subjects: 60
Study: 21745625

Group type: EXPERIMENTAL
Intervention: Fermented kimchi
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fresh kimchi
Number of subjects: 22
Study: 19880459

Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 0
Study: 16412160

Group type: EXPERIMENTAL
Intervention: GnRHa/estradiol
Number of subjects: 21

Group type: COMPARATOR
Intervention: GnRHa/placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Natural menstrual cycles
Number of subjects: 21
Study: 12614703

Group type: EXPERIMENTAL
Intervention: Augmented protocol designed to encourage reflection and deliberation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard protocol for eliciting health preferences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Values-clarification exercise
Number of subjects: 0
Study: 11098040

Group type: EXPERIMENTAL
Intervention: Intercourse during the peri-transfer period
Number of subjects: 478

Group type: COMPARATOR
Intervention: Abstinence from intercourse during the peri-transfer period
Number of subjects: 478
Study: 9360699

Group type: EXPERIMENTAL
Intervention: 1 mL of fibrin glue added to peritoneal cuff suture
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 19
Study: 1544289

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1000 mg quinidine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 4054204

Group type: EXPERIMENTAL
Intervention: Cianergoline (maximum daily dose 12 +/- 2 mg for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cianergoline
Number of subjects: 20
Study: 30269640

Group type: EXPERIMENTAL
Intervention: Automated telemedicine intervention (daily phone messages with proactive alerts)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (daily phone messages without proactive alerts)
Number of subjects: 168
Study: 29914666

Group type: EXPERIMENTAL
Intervention: 800 mg/d resveratrol for 8 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo capsules for 8 weeks
Number of subjects: 45
Study: 28031210

Group type: EXPERIMENTAL
Intervention: EXPERT asthma intervention (interactive website)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 148
Study: 24968101

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 102
Study: 22994055

Group type: EXPERIMENTAL
Intervention: Compound Xuanju Capsule
Number of subjects: 90

Group type: COMPARATOR
Intervention: Antibiotics (Control)
Number of subjects: 90
Study: 20152605

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 200

Group type: COMPARATOR
Intervention: SICS
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Phacoemulsification (automated counting)
Number of subjects: 200

Group type: COMPARATOR
Intervention: SICS (automated counting)
Number of subjects: 200
Study: 18534951

Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 16
Study: 16293868

Group type: EXPERIMENTAL
Intervention: Gemcitabine/carboplatin (GC arm)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Single-agent gemcitabine (G arm)
Number of subjects: 334
Study: 12411222

Group type: EXPERIMENTAL
Intervention: Metergoline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diphenhydramine (active placebo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (unmedicated healthy women)
Number of subjects: 0
Study: 9856962

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9194

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 9194
Study: 7664231

Group type: EXPERIMENTAL
Intervention: Liberal use of episiotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Restrictive use of episiotomy
Number of subjects: 0
Study: 2228843

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 78

Group type: COMPARATOR
Intervention: Clindamycin plus gentamicin
Number of subjects: 78
Study: 396056

Group type: EXPERIMENTAL
Intervention: Praziquantel 3 x 20 mg/kg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Praziquantel 1 x 50 mg/kg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 30948756

Group type: EXPERIMENTAL
Intervention: 150 mg L-DOPA
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 150 mg L-DOPA (low-weight participants)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 30265586

Group type: EXPERIMENTAL
Intervention: Steroid avoidance (SA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Steroid withdrawal (SW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early diagnosis and treatment of glucocorticoid-induced adverse events
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk stratification based on pre-transplant risk factors
Number of subjects: 0
Study: 28069040

Group type: EXPERIMENTAL
Intervention: Acupuncture, electroacupuncture, and intradermal acupuncture (6 sessions within 8 days starting within 48 hours of craniotomy)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acupuncture, electroacupuncture, and intradermal acupuncture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 40
Study: 26229048

Group type: EXPERIMENTAL
Intervention: Early movement of the ankle between neutral and plantar flexion in a brace for 6 weeks (group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Achilles tendon immobilization in tension using a below‐knee cast with the ankle in a neutral position for 6 weeks (group 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 23967631

Group type: EXPERIMENTAL
Intervention: Acupoint sticking + ginger‐separated moxibustion (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Electroacupuncture + ginger‐separated moxibustion (group E)
Number of subjects: 100
Study: 21893447

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/d) for six weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Budesonide (400 ug b.i.d.) for six weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Montelukast and Budesonide
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Budesonide and Montelukast
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Induced sputum analysis
Number of subjects: 41
Study: 18199572

Group type: EXPERIMENTAL
Intervention: Pacing with preventive pacing algorithms (PPA)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Pacing with preventive pacing algorithms (PPA) + anti-tachycardia pacing (ATP)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Pacing with preventive pacing algorithms (PPA) + ATP
Number of subjects: 199
Study: 17018345

Group type: EXPERIMENTAL
Intervention: PMOP 90 bpm for 10 minutes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PMOP 120 bpm for 10 minutes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PMOP 90 bpm for 30 minutes (nonrandomized)
Number of subjects: 50

Group type: COMPARATOR
Intervention: PMOP settings
Number of subjects: 50
Study: 12623744

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg) and selenium (225 microg) supplementation for 3 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Vitamin B (4.5 g/day) for 3 months
Number of subjects: 54
Study: 10846776

Group type: EXPERIMENTAL
Intervention: Middle cerebral artery (MCA) Doppler
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Elevated HC/AC ratio
Number of subjects: 47

Group type: COMPARATOR
Intervention: Normal umbilical artery Doppler waveforms
Number of subjects: 47
Study: 9126892

Group type: EXPERIMENTAL
Intervention: Intravenous therapy with continuous IGF‐I (0.01 mg/kg/hour)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard neurosurgical intensive care plus aggressive nutritional support (Control)
Number of subjects: 33
Study: 8437596

Group type: EXPERIMENTAL
Intervention: Interleukin-1 alpha (0.3 microgram per kilogram after carboplatin)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Interleukin-1 alpha (0.1 or 0.3 microgram per kilogram after carboplatin)
Number of subjects: 43

Group type: COMPARATOR
Intervention: High-dose carboplatin alone (800 mg per square meter)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Interleukin-1 alpha (before carboplatin)
Number of subjects: 43
Study: 3834841

Group type: EXPERIMENTAL
Intervention: Chloroquine chemoprophylaxis
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control (no chloroquine chemoprophylaxis)
Number of subjects: 198
Study: 31971304

Group type: EXPERIMENTAL
Intervention: Dementia Care Competence Scale training
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Dementia care training
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Demographic factors (age, seniority, experience with dementia)
Number of subjects: 308
Study: 31891347

Group type: EXPERIMENTAL
Intervention: Disability simulation activity
Number of subjects: 88

Group type: COMPARATOR
Intervention: Accessibility audit activity
Number of subjects: 88
Study: 29316336

Group type: EXPERIMENTAL
Intervention: Interactive, web‐based parenting tutorial
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 26919410

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg s.c. at baseline, week 1, 2, 3, and 4, then every 4 weeks (with up-titration to 300 mg for 2 non-responders)
Number of subjects: 12
Study: 26366971

Group type: EXPERIMENTAL
Intervention: Caffeine intake
Number of subjects: 1549

Group type: COMPARATOR
Intervention: Creatine intake
Number of subjects: 1549
Study: 22694666

Group type: EXPERIMENTAL
Intervention: Developing Nurses' Thinking (DNT) model during 2 weeks of clinical postconferences
Number of subjects: 83
Study: 20231321

Group type: EXPERIMENTAL
Intervention: No-dose-reduction group (initial optimal therapeutic dose continued throughout the study)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 4-week group (initial optimal therapeutic dose continued for 4 weeks, followed by a 50% dose reduction)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 26-week group (initial optimal therapeutic dose continued for 26 weeks, followed by a 50% dose reduction)
Number of subjects: 404
Study: 18341673

Group type: EXPERIMENTAL
Intervention: Brivaracetam 200 mg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Brivaracetam 400 mg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Brivaracetam 800 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 16122468

Group type: EXPERIMENTAL
Intervention: Controlled additional pulmonary blood flow (group A, n = 29)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Bidirectional Glenn procedure only (group B, n = 9)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Bidirectional Glenn procedure only (group B)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Controlled additional pulmonary blood flow (group A)
Number of subjects: 38
Study: 12689742

Group type: EXPERIMENTAL
Intervention: Personally tailored workbook and telephone counseling program
Number of subjects: 420
Study: 10606361

Group type: EXPERIMENTAL
Intervention: Synacthen depot 0.5 mg on alternate days for 2 injections
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Synacthen depot
Number of subjects: 36
Study: 7594164

Group type: EXPERIMENTAL
Intervention: Behavioral/educational intervention for urinary incontinence
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 101
Study: 2840279

Group type: EXPERIMENTAL
Intervention: Guar biscuit (2.9 g of guar)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Guar biscuit (6.0 g of guar)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Guar biscuit (9.1 g of guar)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control biscuit
Number of subjects: 8
Study: 31865336

Group type: EXPERIMENTAL
Intervention: CTA membrane
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Polyamide membrane
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Polynephron membrane
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Helixone membrane
Number of subjects: 15
Study: 31600472

Group type: EXPERIMENTAL
Intervention: Vocabulary training on Vocabulary.com for a minimum of 20 min, 4 times per week for 4 weeks (total 320 min).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vocabulary training on Vocabulary.com
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study: 28392018

Group type: EXPERIMENTAL
Intervention: SET curriculum training
Number of subjects: 20